A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT01272037

Title field or adapter rule

{'original_value': 'A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer', 'source_field': 'protocolSection.identificationModule.officialTitle'}

Ingested At

2026-10-31T23:27:30.687572+00:00

Published At

2023-06-27T00:00:00+00:00

Record Updated At

2026-10-26

Results Posted At

2023-06-27

Source Retrieved At

2026-10-31T22:18:24.976182+00:00

Timestamp Basis

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Date limitation

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["Breast Ductal Carcinoma In Situ", "Invasive Breast Carcinoma", "Multicentric Breast Carcinoma", "Multifocal Breast Carcinoma", "Synchronous Bilateral Breast Carcinoma"]

protocolSection.statusModule.lastUpdatePostDateStruct

{"date": "2026-10-26", "type": "ACTUAL"}

protocolSection.identificationModule.nctId

"NCT01272037"

protocolSection.identificationModule.officialTitle

"A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer"

protocolSection.statusModule.overallStatus

"ACTIVE_NOT_RECRUITING"

protocolSection.designModule.phases

["PHASE3"]

protocolSection.statusModule.resultsFirstPostDateStruct

{"date": "2023-06-27", "type": "ACTUAL"}

Study condition terms

• Breast Ductal Carcinoma In Situ (protocolSection.conditionsModule.conditions)
• Invasive Breast Carcinoma (protocolSection.conditionsModule.conditions)
• Multicentric Breast Carcinoma (protocolSection.conditionsModule.conditions)
• Multifocal Breast Carcinoma (protocolSection.conditionsModule.conditions)
• Synchronous Bilateral Breast Carcinoma (protocolSection.conditionsModule.conditions)

Interventions recorded in this study

• {'armGroupLabels': ['Arm I (chemotherapy and endocrine therapy)', 'Arm II (endocrine therapy)'], 'description': 'Given PO', 'name': 'Anastrozole', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['Arm I (chemotherapy and endocrine therapy)', 'Arm II (endocrine therapy)'], 'description': 'Given PO', 'name': 'Exemestane', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['Arm I (chemotherapy and endocrine therapy)', 'Arm II (endocrine therapy)'], 'description': 'Correlative studies', 'name': 'Laboratory Biomarker Analysis', 'type': 'OTHER'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['Arm I (chemotherapy and endocrine therapy)', 'Arm II (endocrine therapy)'], 'description': 'Given PO', 'name': 'Letrozole', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['Arm I (chemotherapy and endocrine therapy)', 'Arm II (endocrine therapy)'], 'description': 'Ancillary studies (closed as of 12/1/12)', 'name': 'Quality-of-Life Assessment', 'type': 'OTHER'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['Arm I (chemotherapy and endocrine therapy)'], 'description': 'Given IV', 'name': 'Systemic Chemotherapy', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['Arm I (chemotherapy and endocrine therapy)', 'Arm II (endocrine therapy)'], 'description': 'Given PO', 'name': 'Tamoxifen Citrate', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])

An intervention appearing in a study record does not establish an effect or an approved use.

Drug names recorded in this source

• Anastrozole (protocolSection.armsInterventionsModule.interventions[].name)
• Exemestane (protocolSection.armsInterventionsModule.interventions[].name)
• Letrozole (protocolSection.armsInterventionsModule.interventions[].name)
• Systemic Chemotherapy (protocolSection.armsInterventionsModule.interventions[].name)
• Tamoxifen Citrate (protocolSection.armsInterventionsModule.interventions[].name)

A recorded drug name is not by itself an indication or a condition-specific relationship.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.